In addition to the potential therapeutic approach of GSK-3β [2] in chronic diseases, including cancer [2,7], osteosarcoma [8], leukemia [9,10], rhabdomyosarcoma [5], type 2 diabetes mellitus [11,12], neurodegenerative diseases [13], and inflammation [10,14], GSK-3β has been identified as a negative regulator of a key inducer of bone formation, canonical Wnt/β-catenin [5,6]. This evidence concerns the gene GSK3B and leukemia.